Skip to main content
Clinical Trials/NCT02631681
NCT02631681
Completed
Not Applicable

Supervised Group Based Exercise for Men With Prostate Cancer on Androgen Deprivation Therapy

Herlev Hospital1 site in 1 country200 target enrollmentAugust 2014

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Prostatic Neoplasms
Sponsor
Herlev Hospital
Enrollment
200
Locations
1
Primary Endpoint
Change in 30second Chair-Stand test (30s-CST)
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

Exercise intervention for men with prostate cancer on androgen deprivation therapy.

Detailed Description

The aim of the project is to investigate the effects of patient education and exercise intervention implemented in daily clinical practice for men with prostate cancer on androgen deprivation therapy * Functional capacity * Quality of life * Body composition * Blood pressure and to assess safety of progressive resistance training for participants with bone metastases.

Registry
clinicaltrials.gov
Start Date
August 2014
End Date
September 2017
Last Updated
6 years ago
Study Type
Interventional
Study Design
Single Group
Sex
Male

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Peter Busch Østergren

M.D.

Herlev Hospital

Eligibility Criteria

Inclusion Criteria

  • Patients with a prostate cancer diagnosis on androgen deprivation therapy

Exclusion Criteria

  • Opioid demanding treatment for skeletal pain
  • Eastern Cooperative Oncology Group performance status \> 2
  • Inability to perform floor and machine exercises independently

Outcomes

Primary Outcomes

Change in 30second Chair-Stand test (30s-CST)

Time Frame: Baseline, 12 and 24 weeks

Test of functional capacity, measured as change

Change in Graded Cycling Test with Talk Test (GCT-TT)

Time Frame: Baseline, 12 and 24 weeks

Test of functional capacity, measured as change

Secondary Outcomes

  • change in QoL(Baseline, 12 and 24 weeks)
  • change in Body composition(Baseline, 12 and 24 weeks)
  • change in Bloodpressure(Baseline, 12 and 24 weeks)
  • Safety of exercise assessed by serious adverse events according to the FDA(Study period baseline - 24 weeks)
  • Compliance assessed by attendance and continued exercise (yes/no)(Baseline, 12 and 24 weeks)

Study Sites (1)

Loading locations...

Similar Trials